12968 Federal Register / Vol. 87, No. 45 / Tuesday, March 8, 2022 / Notices 

Dated: March 2, 2022. 

Terrance Perry, 

Chief Grants Management Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. 2022–04788 Filed 3–7–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: NCGC00413972 and Its 

Related Analogs Consisting of an 

Imidazo-Pyrazine Scaffold Core for the 

Treatment or Prevention of Cancers 

Expressing the Mannose Receptor 

CD206, Including Both Solid Tumors 

and Hematological Malignancies 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute, 

an institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Patent License to 

practice the inventions embodied in the 

Patent Applications listed in the 

SUPPLEMENTARY INFORMATION section of 

this notice to Macala Bio, Inc. located in 

1000 NW Wall Street, Suite 220, Bend, 

OR 97703. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Cancer 

Institute’s Technology Transfer Center 

on or before March 23, 2022 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, and 

comments relating to the contemplated 

an Exclusive Patent License should be 

directed to: Eric Cheng, Ph.D., Licensing 

and Patenting Manager at (240)-276– 

5530 or eric.cheng2@nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

United States Provisional Patent 

Application No. 62/950,488, filed 19 

December 2019 and entitled ‘‘CD206 

Modulators Their Use And Methods For 

Preparation’’ [HHS Reference No. E– 

105–2019/0–US–01]; 

PCT Patent Application PCT/US2020/ 

065238, filed 16 December 2020 and 

entitled ‘‘CD206 Modulators Their Use 

And Methods For Preparation’’ [HHS 

Reference No. E–105–2019–0–PCT–02]. 

The patent rights in these inventions 

have been assigned and/or exclusively 

licensed to the government of the 

United States of America. 

The prospective exclusive license 

territory may be worldwide and the 

field of use may be limited to: 

NCGC00413972 and its related analogs 

consisting of an imidazo-pyrazine 

scaffold core for the treatment or 

prevention of cancers expressing the 

mannose receptor CD206, including 

both solid tumors and hematological 

malignancies. 

This technology discloses 

immunotherapy drugs, and to 

compounds that modulate CD206 as 

well as their use and methods for 

preparation. 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

be royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published notice, the National 

Cancer Institute receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR part 404. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially, and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information in these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: March 2, 2022. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2022–04829 Filed 3–7–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Submission for OMB Review; 30-Day 

Comment Request Generic Clearance 

for National Cancer Institute (NCI) NCI 

Resources, Software and Data Sharing 

Forms (National Cancer Institute) 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: In compliance with the 

Paperwork Reduction Act of 1995, the 

National Institutes of Health (NIH) has 

submitted to the Office of Management 

and Budget (OMB) a request for review 

and approval of the information 

collection listed below. 

DATES: Comments regarding this 

information collection are best assured 

of having their full effect if received 

within 30-days of the date of this 

publication. 

ADDRESSES: Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. 

FOR FURTHER INFORMATION CONTACT: To 

obtain a copy of the data collection 

plans and instruments, submit 

comments in writing, or request more 

information on the proposed project, 

contact: Diane Kreinbrink, Office of 

Management Policy and Compliance, 

National Cancer Institute, 9609 Medical 

Center Drive, Rockville, Maryland, 208 

or call non-toll-free number (240) 276– 

7283 or email your request, including 

your address to: diane.kreinbrink@

nih.gov. Formal requests for additional 

plans and instruments must be 

requested in writing. 

SUPPLEMENTARY INFORMATION: This 

proposed information collection was 

previously published in the Federal 

Register on December 20, 2021 (Vol. 86 

FR 71901) and allowed 60 days for 

public comment. No public comments 

were received. The purpose of this 

notice is to allow an additional 30 days 

for public comment. The National 

Cancer Institute (NCI), National 

Institutes of Health (NIH), may not 

conduct or sponsor, and the respondent 

is not required to respond to, an 

information collection that has been 

extended, revised, or implemented on or 

after October 1, 1995, unless it displays 

a currently valid Office of Management 

and Budget (OMB) control number. 

In compliance with Section 

3507(a)(1)(D) of the Paperwork 

Reduction Act of 1995, NIH has 

submitted to OMB a request for review 

and approval of the information 

collection listed below. 

Proposed Collection: Generic 

Clearance for NCI Resources, Software 

and Data Sharing Forms, 0925—NEW, 

Expiration Date xx/xx/xxxx, NCI, NIH. 

Need and Use of Information 

Collection: In preparation for 

dissemination and sharing of data sets, 

forms requesting or applying for access, 

upload, share, and store data will be 

needed. The purpose of data sharing 


lotter on DSK11XQN23PROD with NOTICES1